search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Infection Control & Hospital Epidemiology Table 1. Multimodal Intervention Program


Hospital-wide Interventions Rhode Island Hospital/Hasbro Children’s Hospital


At time of hospital admission, screen patients with signs/symptoms suggestive of respiratory viral infection using nasopharyngeal swabs; if necessary, cohort patients in same room that have the same respiratory virus


Kiosks at hospital entry sites with: cough etiquette poster; alcohol-based hand hygiene dispenser; facial tissues; masks during respiratory virus season (October–April)


Influenza vaccination of staff required by November 30 (unless a valid medical exemption certification is presented); unvaccinated staff wear masks for patient contact when influenza at CDC-defined widespread level in Rhode Island


Contact and droplet isolation for all patients with suspected or confirmed respiratory viral infection


Disallow Hasbro Children’s Hospital visitors < 12 years of age during respiratory virus season (October–April)


Patient care unit–specific interventions Screen visitors on selected patient care units during respiratory virus season (October–April)


Start Dates


RVP October 2009–July 2017 Mean turnaround, 26.6 h; median, 25.6 ha RPP September 2017–present Mean turnaround, 3.2 h; median, 3.0 ha


September 2010 October 2012 November 2015 January 2017 Hasbro Children’s Hospital


- PICU January 2017 - All other children’s hospital units October 2017


Adult hospital - hematology/oncology and solid-organ transplant units November 2017


- Cardiothoracic ICU January 2018 - Respiratory ICU June 2018 - Medical ICU March 2018


Note. RVP, respiratory virus panel; RPP, respiratory pathogen panel (see Methods section for viruses included in both panels). aTurnaround times (ie, time from NP swab of patient to time results reported in electronic medical record) were measured January 1–10, 2017 and 2018 for RVP and RPP, respectively.


363


Table 2. Impact of Visitor Screening on Incidence of Hospital-Acquired Respiratory Viral Infections


Hospital-Acquired Respiratory Viral Infections per 1,000 Patient Care Unit Discharges


Cases Total cases


Visitor screening was not done on patient care unit during 2017–2018 respiratory virus season


Visitor screening was done on patient care unit during 2017–2018 respiratory virus season


Definite cases


Visitor screening was not done on patient care unit during 2017–2018 respiratory virus season


Visitor screening was done on patient care unit during 2017–2018 respiratory virus season


Possible cases


Visitor screening was not done on patient care unit during 2017–2018 respiratory virus season


Visitor screening was done on patient care unit during 2017–2018 respiratory virus season


0.2 0.7 0.4 2.2 2.0 3.1 .26


aVisitor screening was not done during the October 2016–April 2017 respiratory virus season. bHand hygiene compliance in patient care units with no visitor screening and with visitor screening was 82%and91% respectively (P=.001); compliance with isolation precautions was 72%and


60%, respectively (P = .60). cHand hygiene compliance in patient care units with no visitor screening and with visitor screening was 87% and 96% respectively (P < .002); compliance rates with isolation precautions were


89% and 90%, respectively (P = 1.0). d5 coronavirus, 4 influenza, 2 RSV, 2 metapneumovirus, 2 parainfluenza, and 2 rhinovirus/enterovirus. e19 influenza, 10 rhinovirus/enterovirus, 5 metapneumovirus, 4 RSV, 4 viral coinfection, 2 adenovirus, 1 coronavirus, and 2 parainfluenza. f5 RSV, 4 influenza, 2 coronavirus, and 2 enterovirus/rhinovirus. g5 enterovirus/rhinovirus, 5 viral co-infection, 4 RSV, 4 influenza, 1 parainfluenza, 1 metapneumovirus, 1 coronavirus, and 1 adenovirus.


0.7 2.4 2.2 3.1 3.1 1.3 .11 0.9d 3.2f 2.6e 5.3g 2.9 1.7 .67 Oct 2016–Apr 2017a,b Oct 2017–Apr 2018c Rate Ratio P Value


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132